Predictive Value of GDF-15 and sST2 for Pulmonary Hypertension in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

References

• Weitzenblum E, Chaouat A, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease. Pneumonol Alergol Pol. 2013;81:390–398.
   PubMedGoogle Scholar
• Halpin DMG, Criner GJ, Papi A, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. the 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203:24–36. doi:10.1164/rccm.202009-3533SO
   PubMed Web of Science ®Google Scholar
• MacLeod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology. 2021;26:532–551. doi:10.1111/resp.14041
   PubMed Web of Science ®Google Scholar
• Gupta NK, Agrawal RK, Srivastav AB, Ved ML. Echocardiographic evaluation of heart in chronic obstructive pulmonary disease patient and its co-relation with the severity of disease. Lung India. 2011;28:105–109. doi:10.4103/0970-2113.80321
   PubMedGoogle Scholar
• Oswald-Mammosser M, Apprill M, Bachez P, Ehrhart M, Weitzenblum E. Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type. Respiration. 1991;58:304–310. doi:10.1159/000195950
   PubMed Web of Science ®Google Scholar
• Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127:1531–1536. doi:10.1378/chest.127.5.1531
   PubMed Web of Science ®Google Scholar
• Orr R, Smith LJ, Cuttica MJ. Pulmonary hypertension in advanced chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2012;18:138–143. doi:10.1097/MCP.0b013e32834f2093
   PubMed Web of Science ®Google Scholar
• Riley CM, Sciurba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. JAMA. 2019;321:786–797. doi:10.1001/jama.2019.0131
   PubMed Web of Science ®Google Scholar
• Ip C, Luk KS, Yuen VLC, et al. Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: a systematic review and meta-analysis. IJC Heart Vasc. 2021;37:100887. doi:10.1016/j.ijcha.2021.100887
   PubMed Web of Science ®Google Scholar
• Mirna M, Rohm I, Jirak P, et al. Analysis of novel cardiovascular biomarkers in patients with pulmonary hypertension (PH). Heart Lung Circ. 2020;29:337–344. doi:10.1016/j.hlc.2019.03.004
   PubMed Web of Science ®Google Scholar
• Dea A, Ez C, Es B, Az A. Plasma growth differentiation factor-15 in children with pulmonary hypertension associated with congenital heart disease: a canary in the mine? - ScienceDirect. Prog Pediatr Cardiol. 2020;2020:1.
   Google Scholar
• Tantawy AA, Adly AA, Ismail EA, Youssef OI, Ali ME. Growth differentiation factor-15 in children and adolescents with thalassemia intermedia: relation to subclinical atherosclerosis and pulmonary vasculopathy. Blood Cells Mol Dis. 2015;55:144–150. doi:10.1016/j.bcmd.2015.06.001
   PubMed Web of Science ®Google Scholar
• Geenen LW, Baggen VJM, Kauling RM, et al. Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension. Heart. 2020;106:467–473. doi:10.1136/heartjnl-2019-315111
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLB/WHO workshop report, Bethesda, National Heart, Lung and Blood Institute. Www.goldcopd.com. Accessed November 03, 2023.
   Google Scholar
• Gómez Gómez E, Puche Sanz I, Valero Rosa J, Carrasco Valiente J, Campos Hernandez JP, Anglada Curado FJ. Serum biomarkers for diagnosis and characterization of prostate cancer. Arch Esp Urol. 2022;75:156–164.
   PubMed Web of Science ®Google Scholar
• Masuda Y, Matsuda S, Kotani T, et al. Association between serum biomarkers and peripheral neuropathy in microscopic polyangiitis. Int J Mol Sci. 2022;23:13374. doi:10.3390/ijms232113374
   PubMed Web of Science ®Google Scholar
• D’Ascanio M, Viccaro F, Pizzirusso D, et al. Surfactant protein B plasma levels: reliability as a biomarker in COPD patients. Biomedicines. 2023;2023:11.
   Google Scholar
• Andersson J, Fall T, Delicano R, Wennberg P, Jansson JH. GDF-15 is associated with sudden cardiac death due to incident myocardial infarction. Resuscitation. 2020;152:165–169. doi:10.1016/j.resuscitation.2020.05.001
   PubMed Web of Science ®Google Scholar
• Verhamme FM, Seys LJM, De Smet EG, et al. Elevated GDF-15 contributes to pulmonary inflammation upon cigarette smoke exposure. Mucosal Immunol. 2017;10:1400–1411. doi:10.1038/mi.2017.3
   PubMed Web of Science ®Google Scholar
• Mielcarska S, Stopińska K, Dawidowicz M, et al. GDF-15 Level Correlates with CMKLR1 and VEGF-A in tumor-free margin in colorectal cancer. Current Med Sci. 2021;41:522–528. doi:10.1007/s11596-021-2335-0
   PubMed Web of Science ®Google Scholar
• Alladina J, Levy SD, Cho JL, et al. Plasma soluble suppression of tumorigenicity-2 associates with ventilator liberation in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2021;203:1257–1265. doi:10.1164/rccm.202005-1951OC
   PubMed Web of Science ®Google Scholar
• Kim M, Cha SI, Choi KJ, et al. Prognostic value of serum growth differentiation factor-15 in patients with chronic obstructive pulmonary disease exacerbation. Tuberc Respir Dis. 2014;77:243–250. doi:10.4046/trd.2014.77.6.243
   PubMedGoogle Scholar
• Hirano T, Doi K, Matsunaga K, et al. A novel role of growth differentiation factor (GDF)-15 in overlap with sedentary lifestyle and cognitive risk in COPD. J Clin Med. 2020;9. doi:10.3390/jcm9092737
   Web of Science ®Google Scholar
• Havránek Š, Marek J. Biomarker GDF-15 in cardiology. Vnitr Lek. 2021;67:11–14. doi:10.36290/vnl.2021.045
   PubMedGoogle Scholar
• Luo JW, Duan WH, Song L, Yu YQ, Shi DZ. A meta-analysis of growth differentiation factor-15 and prognosis in chronic heart failure. Front Cardiovasc Med. 2021;8:630818. doi:10.3389/fcvm.2021.630818
   PubMed Web of Science ®Google Scholar
• Rueda F, Cediel G, García-García C, et al. Growth differentiation factor 15 and early prognosis after out-of-hospital cardiac arrest. Ann Intensive Care. 2019;9:119. doi:10.1186/s13613-019-0593-9
   PubMed Web of Science ®Google Scholar
• Homsak E, Gruson D. Soluble ST2: a complex and diverse role in several diseases. Clin Chim Acta. 2020;507:75–87. doi:10.1016/j.cca.2020.04.011
   PubMed Web of Science ®Google Scholar
• Carlomagno G, Fazio S. Response to letter by Wang Q et al. regarding article “Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension”. Int J Cardiol. 2013;168:3122. doi:10.1016/j.ijcard.2013.04.051
   PubMed Web of Science ®Google Scholar
• Ye H, Wu Q, Zhang N, et al. The prognostic value of sST2 in connective tissue disease patients with pulmonary hypertension. Rheumatology. 2022;61:3989–3996. doi:10.1093/rheumatology/keac055
   PubMed Web of Science ®Google Scholar
• Plácido R, Cortez-Dias N, Robalo Martins S, et al. Prognostic stratification in pulmonary hypertension: a multi-biomarker approach. Rev Port Cardiol. 2017;36:111–125.
   PubMedGoogle Scholar
• Watanabe M, Nakamoto K, Inui T, et al. Serum sST2 levels predict severe exacerbation of asthma. Respir Res. 2018;19:169. doi:10.1186/s12931-018-0872-2
   PubMed Web of Science ®Google Scholar
• Urban MH, Stojkovic S, Demyanets S, et al. Soluble ST2 and all-cause mortality in patients with chronic obstructive pulmonary disease-a 10-year cohort study. J Clin Med. 2021;11. doi:10.3390/jcm11010011
   PubMedGoogle Scholar